ACTA ENDOCRINOLOGICA (BUC)

Context. For control of blood glucose in diabetic patients on enteral feeding either insulin infusion or multiple insulin injections are used. However, both of these\r\nmethods necessitate a very close follow-up and are not easy to apply during home care.\r\nObjective. In this study we aimed to see whether insulin glargine once daily is proper for glucose regulation in enterally fed diabetic patients.\r\nDESIGN: Insulin glargine is given to enterally fed diabetic patients and they are followed up for three months.\r\nSubjects and methods. Thirteen diabetic stroke patients with PEG are involved in the study. Treatment of these patients is switched from insulin infusion or multiple insulin injections to once daily insulin glargine and they are followed up for 3 months.\r\nResults. Mean blood glucose values are improved with once daily insulin glargine regimen. HbA1c decreased from 7.2% ? 1.5 5. to 6.7% ? 0.8 with insulin glargine. Daily insulin requirement of the patients is significantly decreased as well. A significant decrease in the hypoglycemic episodes is\r\ndetected with glargine (p<0,0001).\r\nConclusion. Insulin glargine once daily is a safe and effective regimen for diabetic patients with PEG.

Objective. Our research investigated the impact of mobile phone distance video education of patients with type II diabetes. This approach was delivered to 100 type 2 diabetes patients based on their cognitive-social factors and metabolic variables. Subjects and Methods. A randomized controlled trial study design was employed. Diabetes education videos were designed and were streamed to the smartphones of the patients. Data were collected from the control (n=50) and experimental (n=50) groups in the first interview, and metabolic control data were recorded. The second interview was held three months after the education process was completed. During this meeting, the survey instrument and the Turkish version of the Multidimensional Diabetes Questionnaire was re-administered to both groups, and metabolic control data were recorded. Results. Following the distance video education, there was a significant decrease in the FPG (1.2 mmol/L) HbA1c (-1.04%), LDL (-0.4 mmol/L) and BMI (-0.7 kg/ m2) values of the experimental group, and their cognitivesocial factors were found to improve in terms of perceiving diabetes. Conclusions. In our study, distance education via mobile phones was an influential approach on cognitivesocial factors and metabolic variables of type 2 diabetes patients.

Context. Despite that the Triglycerides/High Density Lipoprotein Cholesterol (TG/HDL-C) ratio has been associated with insulin resistance and cardiovascular disease, some outcomes differ between populations. Objective. The objective of this study was to evaluate the association between TG/HDL-C ratio and cardio-metabolic risk factors in both obese and normal weight women. Design. Cross sectional, from January to December of 2015. Subjects and Methods. Two hundred and fifty three women aged 40 to 60 years. Anthropometric and laboratory measurements were performed. Insulin resistance was measured by the homeostasis model assessment for insulin resistance (HOMA-IR). All participants underwent a Doppler ultrasound to measure intima-media thickness of carotid artery (cIMT). Results. TG/HDL-C ratio correlated with body mass index (r=0.194, p=0.01), and visceral adipose tissue (r=0.193, p=0.002). Additionally, TG/HDL-C correlated with glucose (r=0.367, p=0.001), insulin (r=0.354, p=0.001) and HOMA-IR (r=0.396 p=0.001). TG/HDL-C was associated with prediabetes, Odds Ratio (OR) was 1.83 (95%CI 1.07-3.13) and insulin resistance 3.27 (95%CI 1.78- 6.01), and this risk remains in normal weight women 4.7 (95%CI 1.2-17.81) for prediabetes and 4.38 (95%CI 1.42- 13.84) for insulin resistance. No significant risk for cIMT. Conclusion. A TG/HDL-C ratio ≥ 3.0 is a potential risk factor for prediabetes and insulin resistance in women 40-60 years, even in normal weight women.

The nuclear receptor coding PPARγ2 (PEROXISOME PROLIFERATORACTIVATED RECEPTOR-GAMMA; *601487) gene influences the lipid and carbohydrate metabolism via multiple pathways and is a candidate for the metabolic syndrome. In this paper we studied the relationship of the CCG (Pro) → GCG (Ala) polymorphism of the gene with the metabolic syndrome diagnosed according to the criteria recommended by the International Diabetes Federation (IDF) in 2005, in a population from central Romania. We have carried out a case-control study on 144 patients and 73 control subjects. Routine biochemical assays have been carried out, fasting insulinemia was measured by ELISA, and insulin sensitivity was assessed by calculating the HOMA and QUICKI indices. Genetic analysis was done by PCR followed by digestion with the restriction enzyme BstU I. The results show that the Pro12 allele had a higher frequency in the group of patients as compared to the healthy controls (76 vs. 65.7%, p<0.05). The risk for developing the metabolic syndrome in the presence of the Pro12 allele in a homozygous combination was found to be low but statistically significant (PP vs. PA + AA: OR = 1.98, CI 95% 1.04 -3.78, p = 0.046). In conclusion, in the local population, the Pro12 allele of the PPARG2 gene seems to contribute to the hereditary predisposition of the metabolic syndrome diagnosed according to the recommendations of the IDF, most likely as part of a polygenic system. Probably the absence of the protective Ala12 allele increases the risk for developing the disease.

Nephrogenic diabetes insipidus (NDI) is the most common renal side effect seen with lithium therapy. Persisting cases after the cessation of the therapy may be seen when lithium therapy is continued for too long. Although desmopressin treatment is not one of the accepted treatment modalities for NDI, there are few reports using desmopressin treatment in unresponsive cases. Herein, we reported the fourth lithium-induced NDI case in the literature responsive to desmopressin therapy.

Idiopathic infantile hypercalcemia (IIH) is a rare, parathyroid hormone (PTH)–independent disorder of calcium metabolism. It is most often caused by mutations in the CYP24A1 gene that impair vitamin D catabolism. We report a 70-year-old male with persistent hypercalcemia (Ca 13.2 mg/dL) and low-normal PTH levels. Extensive evaluation excluded malignancy, granulomatous disease, and vitamin D intoxication. Genetic analysis revealed a homozygous CYP24A1 variant (c.233G>T; p.Gly78Val), consistent with CYP24A1 deficiency. Bisphosphonate therapy with zoledronic acid rapidly and sustainably normalized calcium levels for 10 months. The patient’s daughter was a heterozygous carrier. This confirmed autosomal-recessive inheritance. This case illustrates an atypical late-onset presentation of CYP24A1 deficiency. It emphasizes the importance of considering this diagnosis in adults with PTH-independent hypercalcemia, especially when seasonal variation and family history are present. Recognition of CYP24A1 deficiency at all ages highlights the need for genotype-based terminology rather than the misleading label "infantile" hypercalcemia.

The objective of this study was to investigate the prevalence of hyperthyroidism in Isfahan, a centrally located city in Iran, fifteen years after universal salt iodization. In a cross-sectional study, 2523 Isfahani adult people (aged >20 years, 1275 men and 1248 women) were selected by multistage cluster sampling method. TSH was measured in all (n=2523) and urinary iodine concentration (UIC) in one fourth of participants. Those with low TSH <0.3 mIU/L were recalled and re-tested (n=115). Low TSH with normal FT4I and T3 at the second measurement was considered as subclinical and low TSH with high FT4I or T3 as overt hyperthyroidism. TPOAb, TgAb and UIC were measured in hyperthyroid patients and controls. The prevalence of hyperthyroidism was 1.8 % (n=46): overt-0.8% (n=21) and subclinical hyperthyroidism 1.0% (n=25). Hyperthyroidism was observed in 2.6% of women (n=32) and 1.1% of men (n=14) (OR= 2.4, CI 95%: 1.3-4.5, P=0.006). Iodine deficiency and excess were observed in 21.4% and 18.7% of all population, being 38% and 33% in hyperthyroid patients, respectively (P>0.05). Thyroid function had no statistically significant correlation with iodine intake status. Nobody had UIC more than 100 µg/dl. The prevalence of positive TPOAb and/ or TgAb was 54.5% and 29.2% in hyperthyroid and euthyroid people, respectively (OR= 2.9, CI 95%: 1.2-7, P=0.01). Conclusions:The rate of hyperthyroidism in our region was similar to iodine sufficient areas. Its development is not a direct effect of iodine intake. Antithyroid autoimmunity may have a role.

Aim. Diabetic macular oedema (DME) can develop at all stages of diabetic retinopathy, causing visual impairment and blindness. Modern diets are high in advanced glycation end products (dAGEs), derived from processing methods, exerting a pivotal role in promoting diabetic retinopathy risk. In present study, we investigate the relationship between dietary and serum levels of AGEs and DME in type 2 diabetic subjects. Methods. This case-control study was conducted between July 2018 and February 2019 on 50 case subjects with DME and 40 healthy controls without DM without DME. The sociodemographic characteristics, nutritional status, and anthropometric measurements were evaluated. The advanced glycation end products (AGEs) and receptor for AGEs (sRAGE) levels in serum were analysed. Results. The AGEs levels of the DME group were higher than in the control group (p <0.05). sRAGE levels were higher in the DME group, but not statistically significant (p >0.05). The dietary intake of AGEs was higher in the DME group (p <0.05). It was found that an increase in neck circumference increased the risk of DME (p <0.001). Conclusion. A positive correlation was found between DME and AGEs, dAGE, neck circumference, and waist circumference. For the validity of these results, studies, including controlled nutrition interventions, are needed.

Objective. This study aimed to evaluate the utility of C-peptide levels in the differentiation of monogenic forms of diabetes from type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) in clinical practice. Subjects and Methods. A total of 104 patients aged >16 who visited the Dicle University’s Faculty of Medicine between April 2011 and December 2020 and were diagnosed with monogenic diabetes by genetic analysis or with T1DM and T2DM were randomly selected for retrospective evaluation. The C-peptide levels of these patients at the time of diagnosis of diabetes were compared. Results. Of the 104 patients, 24 (23%) were diagnosed with maturity-onset diabetes of the young (MODY), 40 (38.5%) with T1DM, and 40 (38.5%) with T2DM. Median C-peptide levels (ng/mL) (interquartile range) were 1.78 (1.24–2.88) in MODY group, 0.86 (0.34– 1.22) in T1DM group, and 2.38 (1.58–4.27) in T2DM group. Conclusions. There was a difference in C-peptide levels between MODY and T1DM groups but not between MODY and T2DM groups. As per clinical evaluations, although C-peptide levels of patients with MODY are similar to those of patients with T2DM patients, the possibility of C-peptide levels being similar to those required for T1DM diagnosis should also be considered.

recently. However, the nature of the signals that may connect body fat/muscle tissues with the central nervous system governing energy homeostasis remains to be elucidated. Objective. The present study was designed to investigate the effects of peripheral kisspeptin-10 administration on irisin release in human males. Subjects and methods. Kisspeptin-10 was administered to normal weight (n=8) and obese (n=8) men. Sequential blood sampling was performed for 30 minutes pre and 210 minutes post kisspeptin injection at 30 minutes interval. ELISA kit was used to detect plasma irisin levels. Results. There is a significant (P<0.0001) effect of Kisspeptin-10 administration on irisin release in both normal weight and obese participants. Mean irisin levels (96.24 ± 1.351 ng/mL) at 210 minutes were significantly (P<0.0001) enhanced as compared to pre-kisspeptin (59.18 ± 4.815 ng/ mL) in normal weight subjects. In obese subjects mean irisin levels (75.76 ± 4.06 ng/mL) were significantly (P<0.0001) elevated at 180 minutes post-kisspeptin when compared with pre-kisspeptin irisin levels (41.28 ± 2.89 ng/mL). Conclusion. Our findings suggest that kisspeptin may have a novel therapeutic potential to induce irisin release in humans which may have anti-obesity effects.